Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy - Wikidata - awgldk - TriplyDB

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

http://www.wikidata.org/entity/Q34594769

about

Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma New therapeutic approaches for malignant glioma: in search of the Rosetta stone First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections.The TGF-β-inducible miR-23a cluster attenuates IFN-γ levels and antigen-specific cytotoxicity in human CD8⁺ T cells.Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: functional assays from whole blood as diagnostic clues.Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting.

P2860

Q28068378-AE497893-0AF1-4127-BFDB-8282BADF84D1 Q35104509-5EADD6E1-1FBA-45C6-8736-AF89B1536F44 Q35585735-F140E73D-FDBE-44AB-9C10-EBD67614225C Q36224493-875F9E49-5715-42FD-9300-755175F76520 Q36341084-34DB7156-D1D6-4D49-BC99-150324C30F87 Q37047331-951FFAA0-D998-4F42-B242-4E7BAAEBE959 Q37098840-D13D4A11-1033-4BC1-9263-C45F9BDA8D8A Q37690690-EC3F10B4-07CA-4449-BB4E-A88A22690CF0 Q37919880-467EE2B5-6803-4389-8A13-5F5D846D0E73 Q38768298-6FBB23B9-1655-4535-9549-5684963AE675 Q38974828-56048EB1-FFA6-445C-9864-9EABE01259C5 Q40183378-C754720D-1697-4979-B245-5E1A53CFE178 Q40987686-256C3FAB-381F-4CBF-ABFB-1B679768E144 Q41893704-154B6A6B-262A-4CC7-B6FA-77153741AC38 Q42003336-C294A49E-0CBB-4099-AC5D-CE1727390A8E Q42649288-EA8D9259-6620-4E9C-B0E7-5FA97B47D179 Q46253684-7746710E-C1D0-4B5F-9C22-206949A3FFC2 Q46507832-7F945FED-7E09-42FA-AA3E-C971A02B9630

P2860

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

http://www.wikidata.org/entity/Q34594769

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@ast

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@en

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@nl

type

label

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@ast

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@en

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@nl

prefLabel

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@ast

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@en

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@nl

P1433

Q34594769-C4A23CBE-587E-4E00-A2CC-423DE8DC20F1

P1476

Q34594769-673863C6-896F-41DF-BF13-5BC2004CA5E1

P2093

Q34594769-05E4FB55-5EC6-4F26-8755-40DD41CE2D99

Q34594769-49FC7A83-4D43-444E-862F-5AD4AB80EB76

Q34594769-59512F1A-FB4F-42CF-8C78-FCB0FB950D78

Q34594769-B778A49B-971C-41FD-98D3-F145AF622730

Q34594769-E86D9806-D8C5-40E6-B05B-65FE48906D73

Q34594769-EA902BDB-1A4A-4CEF-8252-60013459B629

P2860

Q34594769-04B2205C-E610-4941-ABE1-CCE6EC9B3C3A

Q34594769-0722CC0F-08F5-472F-A0A2-8A6CE2FFCAF4

Q34594769-0842B6A2-9B5A-46C1-A820-4E16E6AE699C

Q34594769-088325A3-DCC8-4E38-9CFE-482A2F4ACD12

Q34594769-0CB326A4-95B6-4C3A-8FA9-B7E512797A2F

Q34594769-109B6E8B-64D1-4147-81DE-2E6C21B47F06

Q34594769-143DF07C-D364-4286-BEBC-6CBEE2280318

Q34594769-16AAB124-A34B-46B4-A5F1-21C42487E84F

Q34594769-29EF4053-3BF4-4EB8-B885-96212C928A74

Q34594769-2F25595B-8155-4EEE-B5BF-3A4E823F80C7

P2888

Q34594769-99168C4B-0D8E-42E4-8846-D0F75F58C1EB

P304

Q34594769-AB2DFFD9-7200-412D-A594-E9714546F00A

P31

Q34594769-0828CF74-9F5F-46D2-BC8B-E8CA04716DD7

P356

Q34594769-14D32CF1-E23E-4128-95B8-61A0A53A5FAD

P433

Q34594769-BDFE3BD3-76D3-4599-B03F-A0F90804D44B

P478

Q34594769-03B9710E-FE93-4B29-BAC4-43D7B10C7A76

P50

Q34594769-63E54E79-2413-45C8-AA86-B4A9B84F6186

P577

Q34594769-1D59E05D-4F14-4BE1-897C-80D7EC3749EC

P5875

Q34594769-C1EF4937-C969-491F-9CB3-97E323FFA87E

P6179

Q34594769-CA48A5F1-3C43-4781-9759-C61C3EDC2A25

P698

Q34594769-D4DDF9C1-ED9B-4E0E-9894-A39AB39E46BD

P921

Q34594769-61CE7D33-EEE5-47E7-B06E-D0761304E40F

P932

Q34594769-6C8F4539-43E4-40E5-A0DB-9192581ED5B3

P356

S00262-010-0928-8

P1433

Cancer Immunology, Immunotherapy

P1476

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

@en

P2093

Henner Morbach

http://www.w3.org/2001/XMLSchema#string

Katharina Merker

http://www.w3.org/2001/XMLSchema#string

Matthias Wölfl

http://www.w3.org/2001/XMLSchema#string

Paul G Schlegel

http://www.w3.org/2001/XMLSchema#string

Philip D Greenberg

http://www.w3.org/2001/XMLSchema#string

Stefaan W Van Gool

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive immunotherapy for cancer: building on success

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans

Thymic selection generates a large T cell pool recognizing a self-peptide in humans

Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response

IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen

Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor.

MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.

P2888

s00262-010-0928-8

P304

173-186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0928-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Eyrich

P577

2010-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47535554

http://www.w3.org/2001/XMLSchema#string

P6179

1030922590

http://www.w3.org/2001/XMLSchema#string

P698

20972785

http://www.w3.org/2001/XMLSchema#string

P921

P932

3043230

http://www.w3.org/2001/XMLSchema#string